# Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma

> **NCT07316010** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 10 (estimated)

## Conditions studied

- Large B-cell Lymphoma

## Interventions

- **PROCEDURE:** Leukapheresis
- **DRUG:** Lymphodepleting Chemotherapy

## Key facts

- **NCT ID:** NCT07316010
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2029-03-21
- **Final completion:** 2031-03-21
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07316010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07316010, "Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07316010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*